This article was originally published in The Tan Sheet
OTC net sales advanced 18.3 percent to $234.3 million in 2007, "in line with e-commerce trends, but below our expectations due to increased marketing costs in paid search and portals," the e-commerce marketer announces during a Feb. 6 analyst meeting. Gross profit for OTCs during the year advanced 19.8 percent to $69.8 million. For the fourth quarter, OTC revenues were up 17.4 percent to $65.8 million, while gross profit for the period advanced 31.6 percent to $20.5 million. Drugstore.com's net sales for the full year grew 7.2 percent to $445.7 million, though the firm experienced a $9 million loss during the quarter, an improvement over a loss of $13 million last year. In 2008, the company plans to fuel top-line revenue growth in part by driving OTC sales up 20 percent year-over-year, the company says...
You may also be interested in...
Drugstore.com will host an online Rite Aid OTC store slated to launch this year, the companies say Sept. 4. Camp Hill, Pa.-based Rite Aid will receive rights to all Rx drugs ordered online for in-store pickup and will pay drugstore.com $10 million. "Having our own online OTC store and being able to market directly" to the pharmacy chain's customer base "is an important next step in our digital strategy," says Rite Aid Chief Operating Officer Rob Easley. Dawn Lepore, CEO of Bellevue, Wash.-based drugstore.com, says she expects increased sales as "Rite Aid will develop marketing programs to drive traffic to the new site." The e-retailer's 2007 net sales, announced in February, were below expectations due to increased marketing costs (1"The Tan Sheet" Feb. 11, 2008, In Brief)
Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.
COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More
In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.